Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05558267 · ClinicalTrials.gov registry record · NA
Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease
A NA study, sponsored by NYU Langone Health.
- Not yet
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT05558267: Clinical Trial NA study, sponsored by NYU Langone Health.
NCT05558267 is a NA study that has not yet begun recruiting, run by NYU Langone Health. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05558267, a NA study, has not yet begun recruiting, sponsored by NYU Langone Health.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
16 individuals with hemodialysis-dependent end stage kidney disease will receive 16 days of a potassium-containing salt-substitute and 16 days of standard table salt in random order. There will be a 19 day wash out period between the salt-substitute and table salt periods. Potassium concentration will be measured bi-weekly prior to HD each week during intervention. The primary endpoint will be the change in potassium from baseline. Additional measurements will include assessment of dietary intake, ambulatory blood pressure, occurrence of peri-dialytic symptoms, and per-dialytic vital signs.
Primary Outcome
Serum potassium concentration expressed in milliequivalents per liter (mEq/L).
Interventions
- DIETARY_SUPPLEMENT Standard Table Salt
- DIETARY_SUPPLEMENT Salt Substitute
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2027-01-15 |
| Est. Completion | 2027-06-15 |
| Phase | NA |
What is known before NCT05558267 opens enrollment
NCT05558267 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard Table Salt is the first listed.
NCT05558267 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05558267 about?
NCT05558267 is a clinical study titled "Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease". 16 individuals with hemodialysis-dependent end stage kidney disease will receive 16 days of a potassium-containing salt-substitute and 16 days of standard table salt in random order. There will be a 19 day wash out period between the salt-substitute and table salt periods. Potassium concentration wi...
What is the current status of trial NCT05558267?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2027-01-15. Estimated completion is 2027-06-15.
What interventions are being tested in trial NCT05558267?
The interventions under investigation include: Standard Table Salt (DIETARY_SUPPLEMENT), Salt Substitute (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05558267?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05558267's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI